EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 948 participants.

Also called NCT03950076

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 948 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03950076
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Austria, Belgium, Canada, China, Czechia, Egypt, Germany, India, Nepal, Portugal, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03950076. Randomized; single masking; primary purpose prevention. Start 2019-09-20 (actual); primary completion 2026-07-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
Acronym
ENRICH-AF
Condition
Intracranial Hemorrhages
Intervention (Drug)
Edoxaban
Intervention (Other)
Non-anticoagulant medical therapy
Lead sponsor
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct03950076
Content hash
abc5355a8e2b6472f4a127d71542dfe944126cb087741eb422ad52d550146cc0